JKF Headlines
|
In 2007, we made our largest donation since the inception of our Fund. We committed to donate $1,000,000 to The Children’s Hospital of Philadelphia to create something that has never been done before; an endowed Research Chair solely dedicated to finding a cure for pediatric leukemia. Our donation was deemed so important that Children’s Hospital themselves agreed to donate an additional $1,000,000. This $2,000,000 endowment is unprecedented. Once completed The Joshua Kahan Pediatric Leukemia Research Chair will have continual funding to support high quality, state of the art research objectives at one of the best children’s hospital in world. It is our belief that funding like this will give doctors and scientists more tools than ever before and will undoubtedly help us find a cure for pediatric leukemia. |
|
Action news story on 1 million dollar donation presented at 10th Anniversary Dinner Dance for Joshua Kahan Pediatric Leukemia Research Chair. |
|
News Story from The Early Show the 2nd Annual Prom at the Children's Hospital of Philadelphia |
|
|
Leukemia News
Read about the latest Childhood Leukemia research, discoveries, and news
from around the world.
|
|
Science Daily: Leukemia News
-
Researchers have discovered a key reason why chronic myeloid leukemia progresses from its more-treatable chronic phase to a life-threatening phase called blast crisis. The study indicates that CML progresses when immature white blood cells lose a molecule called miR-328 and this traps the cells in a rapidly growing, immature state. The research should provide a better understanding of the blast-crisis stage of CML, and it suggests a possible new treatment strategy for the disease.
-
Scientists studying acute forms of leukemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research reveals how leukaemia cells become 'addicted' to genes, which if targeted could prevent diseased cells from developing.
-
Between 5 and 10 percent of babies with Down syndrome develop a transient form of leukemia that usually resolves on its own. However, for reasons that haven't been clear, 20 to 30 percent of these babies progress to a more serious leukemia known as Down syndrome acute megakaryoblastic leukemia (DS-AMKL), which affects the blood progenitor cells that form red blood cells and platelets. Now, researchers have found a gene regulator they believe to be a key player in DS-AMKL, advancing understanding of how the disease develops and how to treat it.
Society Health News
-
The study indicates that chronic myeloid leukemia (CML) progresses when immature white blood cells lose a molecule called miR-328. Loss of the molecule traps the cells in a rapidly growing, immature state. The cells soon fill the bone marrow and spill into the bloodstream, a tell-tale sign that the disease has advanced to the blast crisis stage.
-
Researchers have found that one particularly aggressive type of blood cancer, mixed lineage leukemia (MLL), has an unusual way to keep the molecular motors running.
-
Adding bortezomib to rituximab, or using single-agent everolimus therapy, look like promising approaches for patients with relapsed or refractory Waldenstrom macroglobulinemia, according to two separate phase II studies reported online February 8th in the Journal of Clinical Oncology.
National Comprehensive Cancer Network
-
-- NCCN to study clinical applications of therapies in treatment of breast, gynecological, and other forms of cancer --
[PEAPACK, NJ] – Pharmacia Corporation today announced it has provided a $3.15 million grant to the National Comprehensive Cancer Network (NCCN) for the development and review of clinical oncology research protocols and trials in breast, gynecological and other forms of cancer. The grant will provide funding for clinical research to identify treatment advances that improve p...
-
Nineteen of the world`s leading cancer centers align to advance
cancer treatment
ROCKLEDGE, PA, June 5, 2002 - The National Comprehensive Cancer
Network (NCCN) announces the launch of its Clinical Trials Network
(CTN), a new strategy for advancing cancer therapies through clinical
trials to improve patient care. A national, centralized infrastructure,
CTN facilitates the initiation of clinical trials by ...
-
ROCKLEDGE, PA, November 5, 2002 – The National Comprehensive Cancer Network (NCCN) today announced changes made to their Web site (www.nccn.org) which will allow physicians to more easily locate clinical trials. Physicians seeking new treatments for their patients with cancer often turn to clinical trials for answers. These research studies include trials testing new treatments, such as a new cancer drug or a new combination of drugs, new approaches to surgery or radiation therapy, or new ther...
Leukemia News From Topix
-
Physicians may be able to safely lower the platelet dosage in transfusions for cancer and bone-marrow transplant patients without risking increased bleeding, according to new research involving UT Southwestern Medical Center and 28 other medical institutions.
-
Dr. Peter J. Pronovost, 45, is medical director of the Quality and Safety Research Group at Johns Hopkins Hospital in Baltimore, which means he leads that institution's quest for safer ways to care for its patients.
-
Last fall life changed for the family of Owen Jensen, a pre-schooler at St. Pius/St Leo's School.